KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Cash & Current Investments (2016 - 2025)

NovoCure's Cash & Current Investments history spans 12 years, with the latest figure at $447.7 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 53.36% year-over-year to $447.7 million; the TTM value through Dec 2025 reached $447.7 million, down 53.36%, while the annual FY2025 figure was $447.7 million, 53.36% down from the prior year.
  • Cash & Current Investments for Q4 2025 was $447.7 million at NovoCure, up from $344.6 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $970.3 million in Q3 2022 and bottomed at $157.5 million in Q2 2023.
  • The 5-year median for Cash & Current Investments is $794.9 million (2021), against an average of $637.5 million.
  • The largest YoY upside for Cash & Current Investments was 441.15% in 2025 against a maximum downside of 64.1% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $209.6 million in 2021, then skyrocketed by 362.49% to $969.4 million in 2022, then fell by 6.07% to $910.6 million in 2023, then increased by 5.41% to $959.9 million in 2024, then tumbled by 53.36% to $447.7 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Cash & Current Investments are $447.7 million (Q4 2025), $344.6 million (Q3 2025), and $911.5 million (Q2 2025).